OPKO Health posted Q2 earnings per share of -$0.01, surpassing the consensus of -$0.08, as revenue rose to $163.5 million and operating loss narrowed to $7.0 million. The beat reduces near‑term cash burn and signals momentum ahead of its first in‑human CAR‑T trial slated for late 2026.
Key Highlights
- EPS of -$0.01 beat consensus for the quarter ended June 30 2026.
- Total revenue climbed to $163.5 million from $156.8 million in the prior year.
- Operating loss improved dramatically to $7.0 million versus $60.0 million a year earlier.
- Phase‑1 in‑vivo CAR‑T trial is slated to begin late 2026 or early 2027.
OPKO Health (NASDAQ: OPK) delivered earnings per share of -$0.01 for the quarter ended June 30 2026, surpassing the consensus estimate. Revenue expanded to $163.5 million, while operating loss narrowed to $7.0 million, a notable improvement from a $60.0 million loss a year earlier. These results illustrate a shift toward stronger top‑line performance and tighter cost control, helping to ease cash‑flow pressures that have weighed on the balance sheet.
EPS Beat Consensus
The reported EPS of -$0.01 contrasted with analyst expectations, representing a meaningful beat. The company also posted a net loss of $8.4 million, reflecting disciplined expense management and higher revenue generation. The reduction in operating loss to $7.0 million stems from lower legacy costs and a more efficient operating structure, indicating that strategic initiatives are beginning to yield results.
Revenue and Cost Dynamics
Consolidated revenue of $163.5 million rose from $156.8 million, driven in part by $46.1 million in intellectual‑property transfers and a $42.9 million product segment. The product line benefited from a favorable $1.8 million foreign‑exchange impact. Total expenses increased modestly to $88.2 million, yet operating income turned positive at $0.8 million, aided by a $18.5 million depreciation and amortization charge.
These dynamics enhance cash generation prospects and provide greater flexibility for research and development investment.
Stock Performance Context
The equity has experienced notable volatility in recent weeks, reflecting mixed investor sentiment despite the earnings beat. Market participants appear to be weighing the company's recent financial improvements against the execution risks associated with its upcoming clinical programs.
Upcoming Catalyst
The firm’s ModeX platform will move into a Phase‑1 in‑vivo CAR‑T study, scheduled to launch in late 2026 or early 2027, targeting autoimmune disease indications. In parallel, the MDX2003 tetraspecific T‑cell engager trial in B‑cell lymphoma continues to enroll patients, with early safety data anticipated in the first half of 2027. These clinical milestones represent key upcoming events that could materially influence the company’s valuation narrative.
Analysis based on the Form 8-K filed 27 July 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...